A high-level overview of Johnson & Johnson (JNJ:CA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
Analyst updates Johnson & Johnson stock price target after earnings This is what could happen next to Johnson & Johnson shares. JNJSWAV STOCKS Apr 16, 2024 4:29 PM EDT Stock Market Today: Stocks lower amid Israel-Iran risks; 2-year yields hit 5% Wall Street faces a busy earnings session...
Stay up-to-date on Johnson & Johnson Common Stock (JNJ) Dividends, Current Yield, Historical Dividend Performance, and Payment Schedule.
Find the latest Johnson & Johnson (JNJ) stock analysis from Seeking Alpha’s top analysts: exclusive research and insights from bulls and bears.
Total returns will also consist of earnings growth and dividends. Given the company’s competitive advantages and recent business performance, we feel that a 6% average annual EPS growth rate is achievable over the next five years. Finally, Johnson & Johnson stock has a current dividend yield of...
Johnson & Johnson Stock Smart Score Unlock Smart Score 1 2 3 4 5 6 7 8 9 10 Show more Top Smart Score Stocks > Company Description Johnson & Johnson Johnson & Johnson provides healthcare products across three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment include...
Get Johnson & Johnson (JNJ:NYSE) real-time stock quotes, news, price and financial information from CNBC.
Withits stock down 6.2% over the past three months, it is easy to disregard Johnson & Johnson (NYSE:JNJ). However, the company's fundamentals look pretty decent, and long-term financials are usuall
Investing News, Analysis, and Tips 3 hours ago Analysts overhaul Tesla stock price target after earnings blowout Elon Musk says Tesla could be "the most valuable company in the world and probably by a long shot." TSLA Business and Finance Breaking News ...
Johnson & Johnson expects to fund the transaction through a combination of cash on hand and short-term financing. Johnson & Johnson expects to maintain a strong balance sheet and to continue to support its stated capital allocation priorities of R&D investment, competitive dividends, value-creating ...